Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

Key Points

• Cagrilintide significantly reduces bodyweight by targeting brain amylin receptors 1 and 3, enhancing energy metabolism.
• An observed reduction of body weight highlights its influence in appetite regulation and energy balance over time.
• Assessment using both biochemical analysis and behavioral tests validates the effects of cagrilintide on bodyweight management.
• Further studies are necessary to explore long-term effects and optimal dosing strategies in diverse populations.